BeiGene: BGB-16673 receives priority drug designation from the European Medicines Agency for the treatment of Waldenstrm's macroglobulinemia.

date
03/08/2025
On July 31st, BeiGene announced that the European Medicines Agency has granted the company Priority Medicine (PRIME) designation for its investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrm's macroglobulinemia who have previously received BTK inhibitor therapy. In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use has also issued a positive opinion on BeiGene's application for orphan drug designation for BGB-16673 in the treatment of WM patients. The final decision is expected to be announced in a few weeks.